A5103097728- Systemic Lupus Erythematosus Research
- Diverticular Disease and Complications
- Intestinal and Peritoneal Adhesions
- Mycobacterium research and diagnosis
- Infectious Diseases and Tuberculosis
- Esophageal and GI Pathology
- Intraperitoneal and Appendiceal Malignancies
- Esophageal Cancer Research and Treatment
- Otitis Media and Relapsing Polychondritis
- Lymphoma Diagnosis and Treatment
- Rheumatoid Arthritis Research and Therapies
- Urticaria and Related Conditions
- Monoclonal and Polyclonal Antibodies Research
- Gastrointestinal Tumor Research and Treatment
- Bone and Joint Diseases
- Tuberculosis Research and Epidemiology
- Vasculitis and related conditions
University of Occupational and Environmental Health Japan
2023-2024
Ashiya University
2023
Abstract Objective To determine the safety and efficacy of anifrolumab in patients with systemic lupus erythematosus (SLE) classified based on Lupus Low Disease Activity State (LLDAS) real-world clinical practice. Methods This retrospective observational study involved SLE who started therapy. The primary end point was retention rate over 26 weeks after initiating therapy; 45 followed up for 12 or longer were analysed following groups to week treatment initiation: (i) non-LLDAS achievement...
Objective To investigate the early detection of pulmonary non-tuberculous mycobacterial (PNTM) disease by CT before initiation molecular-targeted therapeutic drugs in patients with rheumatoid arthritis (RA) and efficacy safety combined treatment antibiotics. Methods Patients RA underwent chest introduction therapies Further Improvement Rheumatoid Treatment registry. The primary endpoint was number who were detected as having PNTM disease, complicating RA. Results Of 4447 CT, 107 had...
To elucidate the differential effects of biological/target synthesized DMARDs (b/tsDMARDs) on bone metabolism in patients with rheumatoid arthritis (RA) a real-world cohort.
The study aimed to determine the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in treatment polymyalgia rheumatica (PMR) complicated by rheumatoid arthritis (RA). Patients with PMR which could be classified as RA who were treated bDMARDs included analysis. primary endpoint was clinical Polymyalgia Rheumatica Activity Score (Clin-PMR-AS) after 26 weeks treatment, secondary adverse events during observation period. A total 203 patients resistant or...